Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers.
Kangho SuhJosh J CarlsonFang XiaTodd WilliamsonSean D SullivanPublished in: Journal of comparative effectiveness research (2022)
Aim: To extrapolate clinical trial results to estimate and compare expected progression-free and overall life years (LYs) and quality-adjusted LYs (QALYs) for larotrectinib and entrectinib in patients with colorectal cancer (CRC), soft tissue sarcoma (STS) and brain metastases prior to treatment with larotrectinib or entrectinib. Methods: A naive direct comparison of larotrectinib versus entrectinib was made using partitioned survival modeling methods from clinical trial data. Results: Larotrectinib resulted in an additional 1.58 LYs (1.17 QALYs), 5.81 LYs (2.02 QALYs) and 1.01 LYs in CRC, STS and baseline brain metastases, respectively, compared with entrectinib. Conclusion: Larotrectinib provided life expectancy and QALY gains compared with entrectinib. Additional studies will be beneficial as more patients are treated and survival data develop to better inform comparative effectiveness results.
Keyphrases
- brain metastases
- small cell lung cancer
- clinical trial
- end stage renal disease
- squamous cell carcinoma
- newly diagnosed
- electronic health record
- open label
- chronic kidney disease
- study protocol
- phase ii
- gene expression
- prognostic factors
- hiv infected
- copy number
- young adults
- combination therapy
- peritoneal dialysis
- patient reported outcomes
- transcription factor
- replacement therapy
- deep learning
- genome wide identification